Literature DB >> 21502498

Modeling high-grade serous ovarian carcinogenesis from the fallopian tube.

Alison M Karst1, Keren Levanon, Ronny Drapkin.   

Abstract

High-grade serous ovarian carcinoma (HGSOC) is a lethal disease for which improved screening and treatment strategies are urgently needed. Progress in these areas is impeded by our poor understanding of HGSOC pathogenesis. Most ovarian cancer research is based on the hypothesis that HGSOC arises from ovarian surface epithelial cells. However, recent studies suggest that >50% of high-grade serous carcinomas involving the ovary likely arise from fallopian tube epithelium. Therefore, limiting HGSOC research to modeling based on ovarian surface epithelium alone is inadequate. To address the need for a fallopian tube-based model of HGSOC, we have developed a system for studying human fallopian tube secretory epithelial cell (FTSEC) transformation. Our model is based on (i) immortalization of FTSECs isolated from primary samples of normal, nondiseased human fallopian tubes, (ii) transformation of FTSECs with defined genetic elements, and (iii) xenograft-based tumorigenic assays. We use our model to show that FTSECs immortalized with human telomerase reverse transcriptase (hTERT) plus SV40 large T and small T antigens are transformed by either oncogenic Ras (H-Ras(V12)) or c-Myc expression, leading to increased proliferation, clonogenicity, and anchorage-independent growth. Additionally, we demonstrate that FTSECs remain susceptible to c-Myc-mediated transformation in the absence of viral oncoproteins, by replacing SV40 large T and small T antigens with sh-p53, mutant CDK4 (CDK4(R24C)), and sh-PP2A-B56γ. Importantly, all transformed FTSECs gave rise to high-grade Müllerian carcinomas that were grossly, histologically, immunophenotypically, and genomically similar to human HGSOC. With this model, we will now be able to assess the transformative effects of specific genetic alterations on FTSECs in order to characterize their respective roles in HGSOC development.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21502498      PMCID: PMC3088633          DOI: 10.1073/pnas.1017300108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

1.  Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship.

Authors:  David W Kindelberger; Yonghee Lee; Alexander Miron; Michelle S Hirsch; Colleen Feltmate; Fabiola Medeiros; Michael J Callahan; Elizabeth O Garner; Robert W Gordon; Chandler Birch; Ross S Berkowitz; Michael G Muto; Christopher P Crum
Journal:  Am J Surg Pathol       Date:  2007-02       Impact factor: 6.394

2.  Emerging roles for PAX8 in ovarian cancer and endosalpingeal development.

Authors:  Nathan J Bowen; Sanjay Logani; Erin B Dickerson; Laura B Kapa; Mariam Akhtar; Benedict B Benigno; John F McDonald
Journal:  Gynecol Oncol       Date:  2006-10-24       Impact factor: 5.482

Review 3.  New insights into the pathogenesis of serous ovarian cancer and its clinical impact.

Authors:  Keren Levanon; Christopher Crum; Ronny Drapkin
Journal:  J Clin Oncol       Date:  2008-10-14       Impact factor: 44.544

4.  A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations.

Authors:  Ann K Folkins; Elke A Jarboe; Aasia Saleemuddin; Yonghee Lee; Michael J Callahan; Ronny Drapkin; Judy E Garber; Michael G Muto; Shelley Tworoger; Christopher P Crum
Journal:  Gynecol Oncol       Date:  2008-03-14       Impact factor: 5.482

Review 5.  The potential of biologic network models in understanding the etiopathogenesis of ovarian cancer.

Authors:  I Khalil; M A Brewer; T Neyarapally; C D Runowicz
Journal:  Gynecol Oncol       Date:  2010-02       Impact factor: 5.482

6.  Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas.

Authors:  Kuan-Ting Kuo; Bin Guan; Yuanjian Feng; Tsui-Lien Mao; Xu Chen; Natini Jinawath; Yue Wang; Robert J Kurman; Ie-Ming Shih; Tian-Li Wang
Journal:  Cancer Res       Date:  2009-04-21       Impact factor: 12.701

7.  A genetically defined model for human ovarian cancer.

Authors:  Jinsong Liu; Gong Yang; Jennifer A Thompson-Lanza; Armand Glassman; Kimberly Hayes; Andrea Patterson; Rebecca T Marquez; Nelly Auersperg; Yinhua Yu; William C Hahn; Gordon B Mills; Robert C Bast
Journal:  Cancer Res       Date:  2004-03-01       Impact factor: 12.701

8.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

9.  Oncogenic transformation of human ovarian surface epithelial cells with defined cellular oncogenes.

Authors:  Rumi Sasaki; Mako Narisawa-Saito; Takashi Yugawa; Masatoshi Fujita; Hironori Tashiro; Hidetaka Katabuchi; Tohru Kiyono
Journal:  Carcinogenesis       Date:  2009-01-06       Impact factor: 4.944

10.  Prognostic relevance of c-MYC gene amplification and polysomy for chromosome 8 in suboptimally-resected, advanced stage epithelial ovarian cancers: a Gynecologic Oncology Group study.

Authors:  Kathleen M Darcy; William E Brady; Jan K Blancato; Robert B Dickson; William J Hoskins; William P McGuire; Michael J Birrer
Journal:  Gynecol Oncol       Date:  2009-06-12       Impact factor: 5.482

View more
  130 in total

1.  The Tyrosine Kinase Adaptor Protein FRS2 Is Oncogenic and Amplified in High-Grade Serous Ovarian Cancer.

Authors:  Leo Y Luo; Eejung Kim; Hiu Wing Cheung; Barbara A Weir; Gavin P Dunn; Rhine R Shen; William C Hahn
Journal:  Mol Cancer Res       Date:  2014-11-03       Impact factor: 5.852

2.  Rethinking ovarian cancer: recommendations for improving outcomes.

Authors:  Sebastian Vaughan; Jermaine I Coward; Robert C Bast; Andy Berchuck; Jonathan S Berek; James D Brenton; George Coukos; Christopher C Crum; Ronny Drapkin; Dariush Etemadmoghadam; Michael Friedlander; Hani Gabra; Stan B Kaye; Chris J Lord; Ernst Lengyel; Douglas A Levine; Iain A McNeish; Usha Menon; Gordon B Mills; Kenneth P Nephew; Amit M Oza; Anil K Sood; Euan A Stronach; Henning Walczak; David D Bowtell; Frances R Balkwill
Journal:  Nat Rev Cancer       Date:  2011-09-23       Impact factor: 60.716

Review 3.  It's Totally Tubular....Riding The New Wave of Ovarian Cancer Research.

Authors:  Ruth Perets; Ronny Drapkin
Journal:  Cancer Res       Date:  2015-12-15       Impact factor: 12.701

4.  Mucinous adenocarcinoma developed from human fallopian tube epithelial cells through defined genetic modifications.

Authors:  Weiwei Shan; Imelda Mercado-Uribe; Jing Zhang; Daniel Rosen; Shiwu Zhang; Jianjun Wei; Jinsong Liu
Journal:  Cell Cycle       Date:  2012-06-01       Impact factor: 4.534

5.  Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention.

Authors:  Tatsuyuki Chiyoda; Peter C Hart; Mark A Eckert; Stephanie M McGregor; Ricardo R Lastra; Ryuji Hamamoto; Yusuke Nakamura; S Diane Yamada; Olufunmilayo I Olopade; Ernst Lengyel; Iris L Romero
Journal:  Cancer Prev Res (Phila)       Date:  2017-03-06

6.  Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer.

Authors:  Ludmila Szabova; Chaoying Yin; Sujata Bupp; Theresa M Guerin; Jerome J Schlomer; Deborah B Householder; Maureen L Baran; Ming Yi; Yurong Song; Wenping Sun; Jonathan E McDunn; Philip L Martin; Terry Van Dyke; Simone Difilippantonio
Journal:  Cancer Res       Date:  2012-05-22       Impact factor: 12.701

7.  Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models.

Authors:  Ruth Perets; Gregory A Wyant; Katherine W Muto; Jonathan G Bijron; Barish B Poole; Kenneth T Chin; Jin Yun H Chen; Anders W Ohman; Corey D Stepule; Soongu Kwak; Alison M Karst; Michelle S Hirsch; Sunita R Setlur; Christopher P Crum; Daniela M Dinulescu; Ronny Drapkin
Journal:  Cancer Cell       Date:  2013-12-09       Impact factor: 31.743

Review 8.  Translating next generation sequencing to practice: opportunities and necessary steps.

Authors:  Sitharthan Kamalakaran; Vinay Varadan; Angel Janevski; Nilanjana Banerjee; David Tuck; W Richard McCombie; Nevenka Dimitrova; Lyndsay N Harris
Journal:  Mol Oncol       Date:  2013-05-15       Impact factor: 6.603

Review 9.  Epithelial ovarian cancer experimental models.

Authors:  E Lengyel; J E Burdette; H A Kenny; D Matei; J Pilrose; P Haluska; K P Nephew; D B Hales; M S Stack
Journal:  Oncogene       Date:  2013-08-12       Impact factor: 9.867

10.  Tight junction proteins claudin-3 and claudin-4 control tumor growth and metastases.

Authors:  Xiying Shang; Xinjian Lin; Edwin Alvarez; Gerald Manorek; Stephen B Howell
Journal:  Neoplasia       Date:  2012-10       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.